Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation

Oncogene volume 19, pages 5487–5497 (2000)Cite this article

Abstract

Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK). We have previously reported that activation of a temperature sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods resulted in subtle changes including, a transient suppression of apoptosis and no inhibition of differentiation. In contrast, activation of the Bcr-Abl PTK for 12 weeks results in cells that display a delay in differentiation at the early granulocyte stage. Flow cytometric analysis also indicates that the expression of cell surface differentiation markers and nuclear morphology are uncoupled. Furthermore, a significant number of the mature neutrophils display abnormal morphological features. Prolonged exposure to Bcr-Abl PTK results in interleukin-3 independent growth and decreased p53 protein levels. FDCP-Mix cells expressing a dominant negative p53 and p53null FDCP-Mix cells demonstrate that the reduction in p53 is causally related to the delay in development. Returning the cells to the restrictive temperature restores the p53 protein levels, the growth factor dependence and largely relieves the effects on development. We conclude that prolonged Bcr-Abl PTK activity within multipotent cells results in a reduction of p53 that drives a delayed and abnormal differentiation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Ahuja H, Bar-Eli M, Advani SH, Benchimol S and Cline MJ. . 1989 Proc. Natl. Acad. Sci. USA 86: 6783–6787.

  • Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A and Cline M. . 1991 J. Clin. Invest. 87: 2042–2047.

  • Amariglio F, Tchang F, Prioleau MN, Soussi T, Cibert C and Mechali M. . 1997 Oncogene 15: 2191–2199.

  • Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, Kraft AS, Nakshatri H and Boswell HS. . 1998 Blood 92: 2450–2460.

  • Carlesso N, Griffin JD and Druker BJ. . 1994 Oncogene 9: 149–156.

  • Clarkson B and Strife A. . 1993 Leukemia 7: 1683–1721.

  • Dai ZH, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GM and Pendergast AM. . 1998 Genes Dev. 12: 1415–1424.

  • Daley GQ and Baltimore D. . 1988 Proc. Natl. Acad. Sci. USA 85: 9312–9316.

  • Daley GQ, Van ER and Baltimore D. . 1990 Science 247: 824–830.

  • Evans CA, Pierce A, Winter SA, Spooncer E, Heyworth CM and Whetton AD. . 1999 Blood 94: 1504–1514.

  • Feinstein E, Gale RP, Reed J and Canaani E. . 1992 Oncogene 7: 1853–1857.

  • Fleming TJ, Fleming ML and Malek TR. . 1993 J. Immunol. 151: 2399–2408.

  • Foti A, Ahuja HG, Allen SL, Koduru P, Schuster MW, Schulman P, Bar-Eli M and Cline MJ. . 1991 Blood 77: 2441–2444.

  • Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN and Ronai Z. . 1998a Genes Dev. 12: 2658–2663.

  • Fuchs SY, Adler V, Pincus MR and Ronai Z. . 1998b Proc. Natl. Acad. Sci. 95: 10541–10546.

  • Gishizky ML and Witte ON. . 1992 Science 256: 836–839.

  • Gotoh A and Broxmeyer HE. . 1997 Curr. Opin. Hematol. 4: 3–11.

  • Griffiths SD, Healy LE, Ford AM, Bennett CA, Voncken JW, Heisterkamp N, Groffen J and Greaves MF. . 1992 Oncogene 7: 1391–1399.

  • Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK and Groffen J. . 1990 Nature 344: 251–253.

  • Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa S, Ishikawa T, Yazaki Y and Hirai H. . 2000 Blood 95: 1144–1150.

  • Jiang X, Lopez A, Holyoake T, Eaves A and Eaves C. . 1999 PNAS 96: 12804–12809.

  • Just U, Stocking C, Spooncer E, Dexter TM and Ostertag W. . 1991 Cell 64: 1163–1173.

  • Kabarowski JH, Allen PB and Wiedemann LM. . 1994 EMBO J. 13: 5887–5895.

  • Kelliher MA, McLaughlin J, Witte ON and Rosenberg N. . 1990 Proc. Natl. Acad. Sci. USA 87: 6649–6653.

  • Klucher KM, Lopez DV and Daley GQ. . 1998 Blood 91: 3927–3934.

  • Konopka JB, Watanabe SM and Witte ON. . 1984 Cell 37: 1035–1042.

  • Kremenetskaya OS, Logacheva NP, Baryshnikov AY, Chumakov PM and Kopnin BP. . 1997 Oncol. Res. 9: 155–166.

  • Laneuville P, Sun G, Timm M and Vekemans M. . 1992 Blood 80: 1788–1797.

  • Leenen PJM, Debrujin MFTR, Voerman JSA, Campbell PA and Vanewijk W. . 1994 J. Immunol. Meth. 174: 5–19.

  • Levine AJ. . 1997 Cell 88: 323–331.

  • Lub M, van Kooyk Y and Figdor CG. . 1996 J. Leukoc. Biol. 59: 648–655.

  • Lugo TG, Pendergast AM, Muller AJ and Witte ON. . 1990 Science 247: 1079–1082.

  • MaguerSatta V, Burl S, Liu L, Damen J, Chahine H, Krystal G, Eaves A and Eaves C. . 1998 Oncogene 16: 237–248.

  • Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J and Deisseroth A. . 1990 Blood 75: 180–189.

  • Mekeel KL, Tang W, Kachnic LA, Luo CM, De Frank JS and Powell SN. . 1997 Oncogene 14: 1847–1857.

  • Metcalf D, Moore MAS, Sheridan JW and Spitzer G. . 1974 Blood 43: 847–859.

  • Nakai H and Misawa S. . 1995 Leuk. Lymphoma 19: 213–221.

  • Nakai H, Misawa S, Horiike S, Maekawa T, Kashima K and Ishizaki K. . 1995 Br. J. Haematol. 90: 147–155.

  • Nakai H, Misawa S, Toguchida J, Yandell DW and Ishizaki K. . 1992 Cancer Res. 52: 6588–6593.

  • Pedersen B. . 1982 Br. J. Haematol. 51: 339–344.

  • Pierce A, Owen-Lynch PJ, Spooncer E, Dexter TM and Whetton AD. . 1998a Oncogene 17: 667–672.

  • Pierce A, Whetton AD, Owen-Lynch PJ, Tavernier E, Spooncer E, Dexter TM and Heyworth CM. . 1998b J. Cell. Sci. 111: 815–823.

  • Prokocimer M and Rotter V. . 1994 Blood 84: 2391–2411.

  • Raitano AB, Halpern JR, Hambuch TM and Sawyers CL. . 1995 Proc. Natl. Acad. Sci. 92: 11746–11750.

  • Rovira A, Urbano-Ispizua A, Cervantes F, Rozman M, Vives-Corrons JL, Montserrat E and Rozman C. . 1995 Ann. Hematol. 70: 129–133.

  • Sabapathy K, Klemm M, Jaenisch R and Wagner EF. . 1997 EMBO J. 16: 6217–6229.

  • Sambrook J, Fritsch EF and Maniatis T. . Molecular Cloning; a laboratory manual, Second edn. Cold Spring Harbor, New York.

  • Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Storkel S, Ortel J, Kolbe K, Huber C, Huhn D and Neubauer A. . 1996 Eur. J. Haematol. 57: 230–240.

  • Shaulian E, Zauberman A, Ginsberg D and Oren M. . 1992 Mol. Cell. Biol. 12: 5581–5592.

  • Shounan Y, Dolinkov A, MacKenzie KL, Miller M, Chan YY and Symonds G. . 1996 Leukemia 10: 1619–1628.

  • Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA and Calabretta B. . 1996 Proc. Natl. Acad. Sci. USA 93: 13137–13142.

  • Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M and Sacchi A. . 1996 J. Cell. Biol. 134: 193–204.

  • Spooncer E, Fairbairn L, Cowling GJ, Dexter TM, Whetton AD and Owen Lynch PJ. . 1994 Leukemia 8: 620–630.

  • Spooncer E, Heyworth CM, Dunn A and Dexter TM. . 1986 Differentiation 31: 111–118.

  • Strife A and Clarkson B. . 1988 Sem. Hematol. 25: 1–19.

  • Sturzbecher HW, Donzelmann B, Henning W, Knippschild U and Buchhop S. . 1996 EMBO J. 15: 1992–2002.

  • Venkatachalam S, Shi Y, Jones SN, Vogel H, Bradley A, Pinkel D and Donehower LA. . 1998 EMBO J. 17: 4657–4667.

  • Verfaille CM. . 1998 Hematology-Oncology Clinics of North America 12: 1.

  • Williams J. . 1995 Williams Hematology. McCraw-Hill Inc: London.

    Google Scholar 

Download references

Acknowledgements

We thank Sue Slack for her excellent technical assistance. This work was supported by the Leukaemia Research Fund and the Cancer Research Campaign.

Author information

Authors and Affiliations

  1. Leukaemia Research Fund Cellular Development Unit, UMIST, Sackville Street, Manchester, M60 1QD, UK

    Andrew Pierce, Sarah Wooley, Julia M Francis, P Jane Owen-Lynch & Anthony D Whetton

  2. Department of Biomolecular Sciences, UMIST, Sackville Street, Manchester, M60 1QD, UK

    Elaine Spooncer & Jaleel Miyan

  3. Department of Experimental Haematology, Cancer Research Campaign, Paterson Institute for Cancer Research, Christie Hospital, NHS Trust, Manchester, M20 9BX, UK

    Elaine Spooncer & T Michael Dexter

  4. Molecular and Cellular Pharmacology Group, School of Biological Sciences, University of Manchester, Manchester, M13 9PT, UK

    Sarah Wooley & Caroline Dive

Authors
  1. Andrew Pierce
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elaine Spooncer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Wooley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caroline Dive
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julia M Francis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jaleel Miyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Jane Owen-Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Michael Dexter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Anthony D Whetton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pierce, A., Spooncer, E., Wooley, S. et al. Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. Oncogene 19, 5487–5497 (2000). https://doi.org/10.1038/sj.onc.1203940

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203940

Keywords

This article is cited by

Search

Advanced search

Quick links